Summary of Key Information:

Reporting Period: Quarter ended 30 September 2026 (Q2 FY27)

Nature of Filing / Announcement: Submission of Unaudited Financial Results & Limited Review Reports (Standalone & Consolidated)

Audit Opinion:

Clean opinion - Limited review report states no material misstatements found

Key Financial Highlights [Rs. in lakh]:

Standalone Results:

Quarter ended 30 September 2026:

  • Revenue from Operations: ₹8,741.61
  • Total Income: ₹8,769.74
  • Net Profit: ₹1,130.69
  • EPS: ₹5.08 (Basic & Diluted)

Quarter ended 30 June 2026 (Q1 FY27):

  • Revenue from Operations: ₹7,297.25
  • Total Income: ₹7,451.64
  • Net Profit: ₹1,028.49
  • EPS: ₹4.62 (Basic & Diluted)

Quarter ended 30 September 2025 (Q2 FY26):

  • Revenue from Operations: ₹5,756.04
  • Total Income: ₹5,877.50
  • Net Profit: ₹453.98
  • EPS: ₹2.03 (Basic & Diluted)

Half Year ended 30 September 2026:

  • Revenue from Operations: ₹16,038.86
  • Total Income: ₹16,221.38
  • Net Profit: ₹2,159.18
  • EPS: ₹9.70 (Basic & Diluted)

Half Year ended 30 September 2025:

  • Revenue from Operations: ₹11,029.66
  • Total Income: ₹11,190.51
  • Net Profit: ₹921.11
  • EPS: ₹4.14 (Basic & Diluted)

Previous Year ended 31 March 2026:

  • Revenue from Operations: ₹25,173.60
  • Total Income: ₹25,402.34
  • Net Profit: ₹3,048.46
  • EPS: ₹13.70 (Basic & Diluted)

Financial Position (Standalone as at 30 September 2026):

  • Other Equity: ₹32,382.65
  • Cash and Cash Equivalents: ₹4.58
  • Bank balance other than above: ₹21.75
  • Total Debt: ₹4,602.12 (Non-current borrowings ₹3,301.14 + Current borrowings ₹1,300.98)
  • Total Assets: ₹51,581.46

Consolidated Results:

The consolidated results are identical to standalone results as the subsidiary (Sakar Oncology Private Limited) has not carried out any business transactions during the reporting period.

Segment-wise Performance:

The Company operates only in one segment: Manufacturing of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not provided.

Corporate Actions:

Not Specified

Other Significant Information:

  • The Company has one wholly owned subsidiary: Sakar Oncology Private Limited
  • No other subsidiaries or associates
  • No exceptional items reported
  • No change in accounting policy affecting comparability
  • No forward-looking guidance or management outlook provided

Cash Flow Highlights (Half Year ended 30 September 2026):

  • Net cashflow from operating activity: ₹2,345.64
  • Net cashflow from investing activity: (₹2,204.39) [Purchase of Property, Plant & Equipment]
  • Net cashflow from financing activity: (₹140.68)
  • Net cash inflow: ₹0.57